Cargando…
The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
INTRODUCTION: Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by self-limited recurrent attacks of fever and serositis. Patients may develop renal amyloidosis. Colchicine prevents attacks and renal amyloidosis. Five to 10 % of the patients with FMF are resistant or...
Autores principales: | Sozeri, Betul, Gulez, Nesrin, Ergin, Malik, Serdaroglu, Erkin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010548/ https://www.ncbi.nlm.nih.gov/pubmed/27590627 http://dx.doi.org/10.1186/s40348-016-0058-2 |
Ejemplares similares
-
Evaluation of familial mediterranean fever patients: a single center experience
por: Gulez, P, et al.
Publicado: (2015) -
Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
por: Kavrul Kayaalp, Gülşah, et al.
Publicado: (2023) -
Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015) -
Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023) -
Deficiency of Adenosine Deaminase 2 Presenting as Periodic Fever at the Mainland of Familial Mediterranean Fever
por: Çakan, Mustafa, et al.
Publicado: (2022)